A possible structural determinant of selectivity of boldine and derivatives for the alpha(1A)-adrenoceptor subtype

被引:33
作者
Madrero, Y
Elorriaga, M
Martinez, S
Noguera, MA
Cassels, BK
DOcon, P
Ivorra, MD
机构
[1] UNIV VALENCIA,FAC FARM,DEPT FARMACOL,E-46100 BURJASSOT,VALENCIA,SPAIN
[2] UNIV CHILE,FAC CIENCIAS,DEPT QUIM,SANTIAGO,CHILE
关键词
alpha(1)-Adrenoceptor subtypes; H-3]-prazosin binding; rat cerebral cortex; aporphine alkaloids; boldine; predicentrine; glaucine;
D O I
10.1111/j.1476-5381.1996.tb16073.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 The selectivity of action of boldine and the related aporphine alkaloids, predicentrine (9-O-methylboldine) and glaucine (2,9-O-dimethylboldine) on alpha(1)-adrenoceptor subtypes was studied by examining [H-3]-prazosin competition binding in rat cerebral cortex. WB 4101 and benoxathian were used as selective alpha(1A)-adrenoceptor antagonists. 2 In the competition experiments [H-3]-prazosin (0.2 nM) binding was inhibited by WE 4101 and benoxathian. The inhibition curves displayed shallow slopes which could be subdivided into high and low affinity components (pK(i)=9.92 and 8.29 for WE 4101, 9.35 and 7.94 for benoxathian). The two antagonists recognized approximately 37% of the sites with high affinity from among the total [H-3]-prazosin specific binding sites. 3 Boldine, predicentrine and glaucine also competed for [3H]-prazosin (0.2 nM) binding with shallow and biphasic curves recognizing 30-40% of the sites with high affinity. Drug affinities (pK(i)) at the high and low affinity sites were, 8.31 and 6.50, respectively, for boldine, 8.13 and 6.39 for predicentrine, and 7.12 and 5.92 for glaucine. The relative order of selectivity for alpha(1A)-adrenoceptors was boldine (70 fold alpha(1A)-selective)=predicentrine (60 fold, alpha(1A)-selective)> glaucine (15 fold, alpha(1A)-selective). 4 Pretreatment of rat cerebral cortex membranes with chloroethylclonidine (CEC, 10 mu M) for 30 min at 37 degrees C followed by thorough washing out reduced specific [H-3]-prazosin binding by approximately 70%. The CEC-insensitive [H-3]-prazosin binding was inhibited by boldine monophasically (Hill slope=0.93) with a single pK(i) value (7.76). 5 These results suggest that whereas the aporphine structure shared by these alkaloids is responsible for their selectivity of action for the alpha(1A)-adrenoceptor subtype in rat cerebral cortex, defined functional groups, namely the 2-hydroxy function, induces a significant increase in alpha(1A)-subtype selectivity and affinity.
引用
收藏
页码:1563 / 1568
页数:6
相关论文
共 52 条
[1]   INVESTIGATION OF THE SUBTYPES OF ALPHA-1-ADRENOCEPTOR MEDIATING CONTRACTIONS OF RAT AORTA, VAS-DEFERENS AND SPLEEN [J].
ABOUD, R ;
SHAFII, M ;
DOCHERTY, JR .
BRITISH JOURNAL OF PHARMACOLOGY, 1993, 109 (01) :80-87
[2]  
ASENCIO M, 1993, BOL SOC CHIL QUIM, V38, P331
[3]  
BECKERINGH J J, 1989, British Journal of Pharmacology, V96, p154P
[4]   FUNCTIONAL EVIDENCE EQUATING THE PHARMACOLOGICALLY-DEFINED ALPHA(1A)-ADRENOCEPTOR AND CLONED ALPHA(1C)-ADRENOCEPTOR - STUDIES IN THE ISOLATED-PERFUSED KIDNEY OF RAT [J].
BLUE, DR ;
BONHAUS, DW ;
FORD, APDW ;
PFISTER, JR ;
SHARIF, NA ;
SHIEH, IA ;
VIMONT, RL ;
WILLIAMS, TJ ;
CLARKE, DE .
BRITISH JOURNAL OF PHARMACOLOGY, 1995, 115 (02) :283-294
[5]   (+)-NIGULDIPINE BINDS WITH VERY HIGH-AFFINITY TO CA-2+ CHANNELS AND TO A SUBTYPE OF ALPHA-1-ADRENOCEPTORS [J].
BOER, R ;
GRASSEGGER, A ;
SCHUDT, C ;
GLOSSMANN, H .
EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, 1989, 172 (02) :131-145
[6]   MECHANISMS OF ACTION OF TRANSMITTERS AND OTHER SUBSTANCES ON SMOOTH-MUSCLE [J].
BOLTON, TB .
PHYSIOLOGICAL REVIEWS, 1979, 59 (03) :606-718
[7]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[8]   MECHANISM OF THE CARDIOVASCULAR ACTIVITY OF LAUDANOSINE - COMPARISON WITH PAPAVERINE AND OTHER BENZYLISOQUINOLINES [J].
CHULIA, S ;
IVORRA, MD ;
LUGNIER, C ;
VILA, E ;
NOGUERA, MA ;
DOCON, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 113 (04) :1377-1385
[9]   MOLECULAR-CLONING AND EXPRESSION OF THE CDNA FOR THE HAMSTER ALPHA-1-ADRENERGIC RECEPTOR [J].
COTECCHIA, S ;
SCHWINN, DA ;
RANDALL, RR ;
LEFKOWITZ, RJ ;
CARON, MG ;
KOBILKA, BK .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (19) :7159-7163
[10]  
CUMISKEY WR, 1983, ARCH INT PHARMACOD T, V263, P113